ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next
ImmunityBio shares soared 17.7% to $6.48 Tuesday after the FDA outlined a possible path for resubmitting ANKTIVA for papillary bladder cancer. The company plans to submit additional requested data within 30 days, with no new trial required. Shares traded between $4.94 and $7.97 on heavy volume. Piper Sandler raised its price target to $7.